VSVanessa Sabella-Jiménez

Vanessa Sabella-Jiménez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vanessa Sabella-Jiménez has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness and safety of the available preventive tuberculosis treatment regimens for children and adolescents: systematic review and network meta-analysis

    by Vanessa Sabella-Jiménez, Dione Benjumea-Bedoya, Yenifer Hoyos-Mendez, Andrés Felipe Estupiñán-Bohorquez, Jorge Acosta-Reyes, Ivan D Florez

    Background: Although children are at a higher risk of progressing to tuberculosis (TB) disease compared with adults, research and publications addressing TB management have mostly emphasised adult disease. Methods: MEDLINE, Embase, CENTRAL and grey literature were searched from inception to 3 May 2021, and updated on 12 December 2024 for the systematic review and network meta-analysis (NMA). Randomised controlled trials of children and/or adolescents under 18 years with TB infection, contacts of drug-susceptible TB, without HIV, evaluating the effectiveness and safety of available regimens for the treatment of TB were included. Meta-analysis was conducted using a random effects model. Risk of bias was assessed using the Cochrane RoB tool 2. Effect estimates (RR and OR) are presented with 95% CIs. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Results: Eleven studies were obtained. All network geometries had open and disconnected loops, except adverse reactions for which we conducted a full NMA. We found that 4 months of isoniazid and rifampicin (4HR) reduces the number of active TB cases at 1 year, 2 years and 5 years of follow-up (RR 0.49 (95% CI 0.32 to 0.76)) compared with isoniazid for 9 months (9H). The isoniazid + rifapentine for 3 months (3HP) regimen (RR 1.09 (95% CI 1.03 to 1.15)), 4HR (RR 1.07 (95% CI 1.01 to 1.14)) and rifampicin for 4 months (4R) (RR 1.12 (95% CI 1.05 to 1.20)) regimens have higher treatment adherence compared with 9H. High variability was found in the reporting of adverse reactions, which were more likely to occur with 3HP compared with 4HR (OR 4.56 (95% CI 1.22 to 16.96)) and 4R (OR 6.37 (95% CI 2.11 to 19.19)). Adverse reactions occur less frequently with 4R (OR 0.34 (95% CI 0.20 to 0.58)) compared with 9H. Conclusions: This study synthesised available data on paediatric short and long-course regimens. Short course regimens may have higher adherence (3HP, 4HR, 4R) and may reduce active TB incidence (isoniazid + rifampicin for 3 months (3HR) and 4HR) compared with 9H. PROSPERO registration number: CRD42021271512.

  • Open Access

    Utility of Xpert MTB/RIF using bronchoalveolar lavage samples for the diagnosis of pulmonary tuberculosis in negative or sputum-scarce adults: a systematic review and meta-analysis protocol

    by Valentina L Sabella-Jiménez, Vanessa Sabella-Jiménez, Andrés Felipe Estupinan-Bohorquez, Jorge Acosta-Reyes

    Introduction: Tuberculosis is the leading cause of death globally from a single infectious agent. Early diagnosis is critical to reducing morbimortality. In cases of negative smear microscopy or limited sputum production, bronchoalveolar lavage (BAL) samples offer an alternative for diagnosis. Culture, the gold standard, requires a high bacterial load, extensive infrastructure and is time-consuming. Xpert MTB/RIF provides faster results with a higher cost. Previous systematic reviews present substantial limitations, including significant heterogeneity. Therefore, the diagnostic utility of Xpert MTB/RIF using BAL samples in adults with negative or scant sputum for pulmonary tuberculosis (PTB) needs to be reassessed. Methods and analysis: A systematic search of MEDLINE, Embase, LILACS and Web of Science will be conducted without language or publication date restriction. Cross-sectional diagnostic studies of negative or sputum-scarce adults with presumptive PTB who underwent bronchoscopy to obtain samples for Xpert MTB/RIF and culture will be included. Screening and data extraction will be performed independently. Methodological quality will be assessed using the QUADAS-2 tool. A bivariate hierarchical random-effects model will synthesise sensitivity and specificity. Meta-analysis will be performed using Meta-DiSc 2.0. Heterogeneity will be assessed using I 2 and Cochrane thresholds. Subgroup analyses will be performed based on study design, population differences, country, culture method and risk of bias. Publication bias will be investigated using a funnel plot. The certainty of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach. There was no patient or public involvement in the development of the systematic review protocol. Ethics and dissemination: Ethical approval is not required as this study will use publicly available data. Findings will be disseminated through peer-reviewed publication. PROSPERO registration number: CRD42025639440.

  • Open Access

    Guía de práctica clínica para la evaluación, tratamiento y seguimiento de niños contacto de pacientes con tuberculosis pulmonar en Colombia

    by Dione Benjumea-Bedoya, Jaime Robledo-Restrepo, María Patricia Arbeláez-Montoya, Andrés Felipe Estupiñán-Bohórquez, Vanessa Sabella-Jiménez, Andrea Victoria Restrepo-Gouzy, Claudia Beltran-Arroyave, Jairo Bedoya-Giraldo, Jürg Niederbacher-Velasquez, Isabel Cristina Hurtado-Palacios, et al.

    Introducción: Las guías de práctica clínica (GPC) disponibles sobre infección latente por tuberculosis (ILTB) no son exclusivas de población pediátrica. Objetivo: Desarrollar recomendaciones basadas en evidencia para evaluación, tratamiento y seguimiento de niños contacto de pacientes con tuberculosis (TB) pulmonar en Colombia Métodos: Conformamos un grupo desarrollador multidisciplinario (expertos clínicos, de campo, investigadores, y metodólogos), representante de pacientes y tomadores de decisión. Construimos 10 preguntas y priorizamos desenlaces sobre diagnóstico (evaluación clínica, radiografía de tórax y pruebas de liberación de interferón gamma-IGRA), tratamiento (eficacia de regímenes en distinos escenarios) y seguimiento (monitoreo y estrategias para incrementar adherencia) del niño con ILTB. Realizamos revisiones sistemáticas de literatura para identificar guías, revisiones de literatura y estudios primarios. Evaluamos calidad y riesgos de sesgos de estos con herramientas específicas. Sintetizamos la evidencia de forma narrativa, y en algunos casos con metanálisis de novo (diagnósticos y en red). Evaluamos la certeza de la evidencia con sistema GRADE. Utilizamos el marco de la evidencia a la recomendación de GRADE para guiar el proceso de recomendaciones. Resultados: El grupo recomienda el uso de radiografía, y prueba de IGRA en niños contacto para identificar tubercolosis activa. Recomendamos regímenes cortos en lugar de largos en niños con y sin inmunosupresión y regímenes guiados según susceptibilidad en casos de contacto con TB resistente. Recomendamos seguimiento clínico mensual y la implementación de abordajes integrales para identificar las barreras para incentivar la adherencia al tratamiento. Conclusiones: El grupo aporta recomendaciones basadas en la evidencia contextualizadas para los niños con ILTB en Colombia.


  • Open Access

    Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis

    by Vanessa Sabella-Jiménez, Yenifer Hoyos Mendez, Dione Benjumea-Bedoya, Andrés Felipe Estupiñán-Bohorquez, Jorge Acosta-Reyes, Ivan D Florez

    Introduction: Approximately 5%–10% of individuals with untreated latent tuberculosis infection (LTBI) will progress to active tuberculosis (TB). Children are at a higher risk for progression to TB disease than adults. Isoniazid prophylaxis treatment period is long and can cause liver damage. Alternatives to isoniazid, such as rifamycin containing regimens, should be considered for prophylaxis. Previous systematic reviews, with different study designs and data combining results on children and adults, have evaluated the comparative efficacy and harms of LTBI treatment regimens. We aim to determine the effectiveness and safety of all the different regimens available for the treatment of LTBI for children and adolescents less than 18 years of age, contacts of drug-susceptible TB, without HIV infection.Methods and analysis: MEDLINE, Embase and Cochrane Central Register of Controlled Trials will be systematically searched for randomised controlled trials without any language or publication date restriction. Screening and extraction will be performed in duplicate. Risk of bias will be performed in duplicate with Cochrane Risk of Bias tool V.2. Pairwise meta-analysis of direct comparisons and network meta-analyses (NMAs) will be performed. Heterogeneity will be assessed using I2 and Cochrane thresholds. Direct and indirect estimates in an NMA will be combined if justifiable. Subgroups analyses will be performed in different mean age and study year groups. Sensitivity analysis based on the risk of bias will be conducted. Publication bias will be investigated using funnel plots and Egger’s regression test. Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria will assess certainty of the evidence for the direct comparisons. GRADE approach for NMA will assess the quality of the evidence from the indirect and NMA.Ethics and dissemination: Ethical approval is not required as no primary data are collected. This systematic review will be disseminated in a peer-reviewed journal.PROSPERO registration number: CRD42021271512.


  • Open Access

    Mitochondrial DNA deletion and duplication in Kearns–Sayre Syndrome (KSS) with initial presentation as Pearson Marrow‐Pancreas Syndrome (PMPS): Two case reports in Barranquilla, Colombia

    by Vanessa Sabella‐Jiménez, Carlos Otero‐Herrera, Carlos Silvera‐Redondo, Pilar Garavito‐Galofre

    Background: Kearns–Sayre Syndrome (KSS) and Pearson Marrow‐Pancreas Syndrome (PMPS) are among the classic phenotypes caused by mitochondrial DNA (mtDNA) deletions. KSS is a rare mitochondrial disease defined by a classic triad of progressive external ophthalmoplegia, atypical pigmentary retinopathy, and onset before 20 years. PMPS presents in the first year of life with bone marrow failure and exocrine pancreatic dysfunction, and can evolve into KSS later in life. Even though an mtDNA deletion is the most frequent mutation in KSS and PMPS, cases of duplications and molecular rearrangements have also been described. In Colombia, few case reports of KSS and PMPS have been published in indexed journals or have been registered in scientific events.Methods: We discuss clinical and genetic aspects of two case reports of pediatric female patients, with initial clinical diagnosis of PMPS who later evolved into KSS, with confirmatory molecular studies of an mtDNA deletion and an mtDNA duplication.Results: A large‐scale mtDNA deletion, NC_012920.1:m.8286_14416del, was confirmed by Southern Blot in patient 1. An mtDNA duplication of 7.9 kb was confirmed by MLPA in patient 2.Conclusions: Our findings are compatible with the phenotypic and genetic presentation of PMPS and KSS. We present the first molecularly confirmed case reports of Colombian patients, diagnosed initially with PMPS, who later evolved to KSS.


  • Open Access

    Caracterización de pacientes con demencia de tipo Alzheimer precoz vs tardío

    by Nohemí Meza Cely, Vanessa Sabella-Jiménez, Jorge Luis Acosta-Reyes, Carlos Alberto Otero-Herrera, Maria Susana Perez-Olivo, Dania Lucia Ruiz-Plaza, Dennys Paola Jiménez Hernández, Carlos Arturo Silvera-Redondo, Gloria María Rolón Martínez

    Introducción: La Enfermedad de Alzheimer (EA) tiene presentación precoz o tardía. Es necesaria mayor información sobre factores de riesgo según edad de aparición de EA. El objetivo es caracterizar variables sociodemográficas, antropométricas, de laboratorio, genéticas y antecedentes en pacientes con EA de novo según edad de aparición en el departamento del Atlántico, Colombia en un periodo de dos años. Metodología: Estudio descriptivo transversal con 39 pacientes con diagnóstico de EA de novo. Se realizó un cuestionario, se solicitaron paraclínicos y se obtuvo una muestra sanguínea para genotipificación de APOE. Se utilizó el software IBM SPSS 21 para análisis. Resultados: El 82,05% tenían EA tardío y 17,95%, EA precoz. El 69,23% era femenino. El 71,44% con EA precoz eran casados y 53,12% con EA tardío eran viudos. Solo 14,29% con EA precoz tenían niveles óptimos de LDL, similar al grupo tardío (18,75%). El 79,49% era heterocigoto para el alelo ε4. El 71,43% con EA precoz tenía antecedente familiar de demencia. Discusión: La edad es el factor de riesgo más importante y el sexo femenino tiene una mayor incidencia por mayor expectativa de vida. Las relaciones sociales juegan un rol en el desarrollo de la enfermedad y en el diagnóstico precoz o estadios iniciales. El aumento del LDL y disminución del HDL se presentan en individuos con mayor deterioro neuronal, especialmente ante la presencia del alelo ε4 del gen APOE, por disminución del catabolismo de LDL plasmático. Tener un alelo ε4 y un familiar con demencia aumenta la probabilidad de padecer EA.


      • Vol. 56  (1)
    Open Access

    Clinical practice guideline for the evaluation, treatment, and follow-up of children in contact with patients with pulmonary tuberculosis in Colombia

    by Dione Benjumea-Bedoya, Jaime Alberto Robledo-Restrepo, Maria Patricia Arbelaez-Montoya, Andres Felipe Estupiñán-Bohorquez, Vanessa Sofia Sabella-Jimenez, Andrea Victoria Restrepo-Gouzy, Claudia Patricia Beltran-Arroyave, Jairo Bedoya-Giraldo, Jurg Niederbacher-Velasquez, Isabel Cristina Hurtado-Palacios, et al.

    The available clinical practice guidelines on tuberculosis infection are not exclusive to the pediatric population. To formulate evidence-based recommendations for the evaluation, treatment, and follow-up of children in contact with patients with pulmonary tuberculosis in Colombia. A multidisciplinary development panel (composed by clinical and field experts, researchers, and methodologists who declared conflicts of interests), including patient representatives, and decision-makers formulated 10 questions and prioritized outcomes related to diagnosis (clinical evaluation, chest X-ray, and interferon-gamma release assays-IGRA), treatment (efficacy of regimens in different clinical scenarios), and follow-up (monitoring and strategies to increase adherence) for children exposed to tuberculosis. We conducted systematic literature reviews to identify guidelines, systematic reviews, and primary studies. We assessed these sources' quality and risk of bias with specific tools. We synthesized the evidence narratively and, in some cases, performed de novo meta-analyses (diagnostic and network meta-analyses). We evaluated the certainty of evidence using the GRADE system. We used the GRADE evidence-to-recommendation framework to formulate the recommendations. We recommend 1) the use of IGRA tests to identify tuberculosis infection and chest X-rays to screen for active tuberculosis in children exposed to tuberculosis, 2) short instead of extended regimens for children with and without immunosuppression, 3) levofloxacin or susceptibility-guided regimens in cases of contact with drug-resistant tuberculosis, 4) monthly clinical follow-up during the treatment, 5) the implementation of comprehensive approaches to identify barriers to encourage treatment adherence. The guideline panel provides context-specific, evidence-based recommendations for assessing and treating children exposed to tuberculosis in Colombia.